^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G12R

    i
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    DC Vaccine in Pancreatic Cancer (NCT03592888)
    Phase 1
    University of Pennsylvania
    Completed
    Last update posted :
    05/07/2024
    Initiation :
    11/20/2018
    Primary completion :
    02/12/2024
    Completion :
    02/12/2024
    KRAS • HLA-A
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11
    A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy (NCT05630989)
    Phase N/A
    Mandana Kamgar, MD
    Recruiting
    Last update posted :
    04/11/2024
    Initiation :
    02/07/2023
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    KRAS
    |
    KRAS mutation • KRAS G12R • KRAS G12
    |
    hydroxychloroquine
    KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC (NCT05254184)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    01/24/2024
    Initiation :
    11/01/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations (NCT03040986)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/09/2021
    Initiation :
    07/21/2017
    Primary completion :
    08/10/2018
    Completion :
    10/15/2020
    KRAS • RAS
    |
    KRAS mutation • KRAS wild-type • KRAS G12R • RAS wild-type • KRAS G12
    |
    Koselugo (selumetinib)